Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Bioactive Sphene-Based Ceramic Coatings on cpTi Substrates for Dental Implants: An In Vitro Study.

Elsayed H, Brunello G, Gardin C, Ferroni L, Badocco D, Pastore P, Sivolella S, Zavan B, Biasetto L.

Materials (Basel). 2018 Nov 9;11(11). pii: E2234. doi: 10.3390/ma11112234.

2.

In Vitro Effect of Bromelain on the Regenerative Properties of Mesenchymal Stem Cells.

Ghensi P, Cucchi A, Bonaccorso A, Ferroni L, Gardin C, Mortellaro C, Zavan B.

J Craniofac Surg. 2018 Oct 24. doi: 10.1097/SCS.0000000000004862. [Epub ahead of print]

PMID:
30358745
3.

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial.

Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S.

Haematologica. 2018 Aug 3. pii: haematol.2018.188888. doi: 10.3324/haematol.2018.188888. [Epub ahead of print]

4.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

Adès L, Thomas X, Guerci Bresler A, Raffoux E, Spertini O, Vey N, Marchand T, Récher C, Pigneux A, Girault S, Deconinck E, Gardin C, Tournilhac O, Lambert JF, Chevallier P, de Botton S, Lejeune J, Dombret H, Chevret S, Fenaux P; French Belgian Swiss APL group.

Haematologica. 2018 Jul 19. pii: haematol.2018.198614. doi: 10.3324/haematol.2018.198614. [Epub ahead of print]

5.

Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.

Kelaidi C, Braun T, Arana R, Marceau-Renaut A, Lazarian G, Soret J, Cereja S, Letestu R, Eclache V, Lusina D, Baran-Marszak F, Ades L, Preudhomme C, Martin A, Fenaux P, Gardin C.

Leuk Res. 2018 Aug;71:67-74. doi: 10.1016/j.leukres.2018.05.007. Epub 2018 May 29.

PMID:
30025278
6.

Biocompatibility and antibacterial properties of zirconium nitride coating on titanium abutments: An in vitro study.

Brunello G, Brun P, Gardin C, Ferroni L, Bressan E, Meneghello R, Zavan B, Sivolella S.

PLoS One. 2018 Jun 26;13(6):e0199591. doi: 10.1371/journal.pone.0199591. eCollection 2018.

7.

Graphene-Based Nanomaterials for Tissue Engineering in the Dental Field.

Guazzo R, Gardin C, Bellin G, Sbricoli L, Ferroni L, Ludovichetti FS, Piattelli A, Antoniac I, Bressan E, Zavan B.

Nanomaterials (Basel). 2018 May 20;8(5). pii: E349. doi: 10.3390/nano8050349. Review.

8.

Pulsed electromagnetic fields increase osteogenetic commitment of MSCs via the mTOR pathway in TNF-α mediated inflammatory conditions: an in-vitro study.

Ferroni L, Gardin C, Dolkart O, Salai M, Barak S, Piattelli A, Amir-Barak H, Zavan B.

Sci Rep. 2018 Mar 23;8(1):5108. doi: 10.1038/s41598-018-23499-9.

9.

Autologous Fat Transfer for Facial Augmentation and Regeneration: Role of Mesenchymal Stem Cells.

Clauser L, Lucchi A, Tocco-Tussardi I, Gardin C, Zavan B.

Atlas Oral Maxillofac Surg Clin North Am. 2018 Mar;26(1):25-32. doi: 10.1016/j.cxom.2017.10.002. Review. No abstract available.

PMID:
29362068
10.

The Biological Properties of OGI Surfaces Positively Act on Osteogenic and Angiogenic Commitment of Mesenchymal Stem Cells.

Ghensi P, Bressan E, Gardin C, Ferroni L, Soldini MC, Mandelli F, Soldini C, Zavan B.

Materials (Basel). 2017 Nov 17;10(11). pii: E1321. doi: 10.3390/ma10111321.

11.

Treatment of diabetic foot ulcers with Therapeutic Magnetic Resonance (TMR®) improves the quality of granulation tissue.

Ferroni L, Gardin C, De Pieri A, Sambataro M, Seganfreddo E, Goretti C, Iacopi E, Zavan B, Piaggesi A.

Eur J Histochem. 2017 Aug 7;61(3):2800. doi: 10.4081/ejh.2017.2800.

12.

Porcine Bone Scaffolds Adsorb Growth Factors Secreted by MSCs and Improve Bone Tissue Repair.

Mijiritsky E, Ferroni L, Gardin C, Bressan E, Zanette G, Piattelli A, Zavan B.

Materials (Basel). 2017 Sep 8;10(9). pii: E1054. doi: 10.3390/ma10091054.

13.

Release of VEGF from Dental Implant Improves Osteogenetic Process: Preliminary In Vitro Tests.

Zavan B, Ferroni L, Gardin C, Sivolella S, Piattelli A, Mijiritsky E.

Materials (Basel). 2017 Sep 8;10(9). pii: E1052. doi: 10.3390/ma10091052.

14.

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

Falantes J, Pleyer L, Thépot S, Almeida AM, Maurillo L, Martínez-Robles V, Stauder R, Itzykson R, Pinto R, Venditti A, Bargay J, Burgstaller S, Martínez MP, Seegers V, Cortesão E, Foncillas MÁ, Gardin C, Montesinos P, Musto P, Fenaux P, Greil R, Sanz MA, Ramos F; European ALMA + Investigators.

Leuk Lymphoma. 2018 May;59(5):1113-1120. doi: 10.1080/10428194.2017.1365854. Epub 2017 Aug 24.

PMID:
28838276
15.

Bioactive Glass-Ceramic Scaffolds from Novel 'Inorganic Gel Casting' and Sinter-Crystallization.

Elsayed H, Rincón Romero A, Ferroni L, Gardin C, Zavan B, Bernardo E.

Materials (Basel). 2017 Feb 13;10(2). pii: E171. doi: 10.3390/ma10020171.

16.

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).

Braun T, Gardin C.

Expert Opin Investig Drugs. 2017 Jul;26(7):803-811. doi: 10.1080/13543784.2017.1335711. Epub 2017 Jun 9. Review.

PMID:
28541716
17.

Hypomethylating Agents as a Therapy for AML.

Gardin C, Dombret H.

Curr Hematol Malig Rep. 2017 Feb;12(1):1-10. doi: 10.1007/s11899-017-0363-4. Review.

PMID:
28286907
18.

Osteo Growth Induction titanium surface treatment reduces ROS production of mesenchymal stem cells increasing their osteogenic commitment.

Ghensi P, Bressan E, Gardin C, Ferroni L, Ruffato L, Caberlotto M, Soldini C, Zavan B.

Mater Sci Eng C Mater Biol Appl. 2017 May 1;74:389-398. doi: 10.1016/j.msec.2016.12.032. Epub 2016 Dec 9.

PMID:
28254309
19.

Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain.

Rimessi A, Pavan C, Ioannidi E, Nigro F, Morganti C, Brugnoli A, Longo F, Gardin C, Ferroni L, Morari M, Vindigni V, Zavan B, Pinton P.

Neuropsychopharmacology. 2017 Jun;42(7):1491-1501. doi: 10.1038/npp.2017.20. Epub 2017 Jan 27.

20.

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.

Ades L, Prebet T, Stamatoullas A, Recher C, Guieze R, Raffoux E, Bouabdallah K, Hunault M, Wattel E, Stalnikiewicz L, Toma A, Dombret H, Vey N, Sebert M, Gardin C, Chaffaut C, Chevret S, Fenaux P.

Haematologica. 2017 Apr;102(4):728-735. doi: 10.3324/haematol.2016.151894. Epub 2016 Dec 29.

21.

HBME-1 is expressed by erythroid precursors in early maturation stage and can be a valuable tool for evaluation of dyserythropoiesis in bone marrow core biopsy specimens.

Arana R, Lusina D, Braun T, Letestu R, Gardin C, Martin A.

J Clin Pathol. 2016 Oct;69(10):933-7. doi: 10.1136/jclinpath-2016-203850. Epub 2016 Aug 2.

PMID:
27484914
22.

Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review.

Grignano E, Mekinian A, Braun T, Liozon E, Hamidou M, Decaux O, Puéchal X, Kahn JE, Schoindre Y, Rossignol J, Lortholary O, Lioger B, Hermine O, Park S, Ades L, Montestruc F, Ricard L, Gardin C, Fenaux P, Fain O; GFM, SNFMI and CRI.

Leuk Res. 2016 Aug;47:136-41. doi: 10.1016/j.leukres.2016.05.013. Epub 2016 Jun 2.

23.

Non-Washed Resorbable Blasting Media (NWRBM) on Titanium Surfaces could Enhance Osteogenic Properties of MSCs through Increase of miRNA-196a And VCAM1.

Gardin C, Ferroni L, Piattelli A, SIvolella S, Zavan B, Mijiritsky E.

Stem Cell Rev. 2016 Oct;12(5):543-552.

PMID:
27318850
24.

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.

Thépot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prébet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastié JN, Delaunay J, Chaury MP, Sanhes L, Wattel E, Dreyfus F, Vey N, Chermat F, Preudhomme C, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2016 Aug;101(8):918-25. doi: 10.3324/haematol.2015.140988. Epub 2016 May 26.

25.

Powder-based 3D printing for bone tissue engineering.

Brunello G, Sivolella S, Meneghello R, Ferroni L, Gardin C, Piattelli A, Zavan B, Bressan E.

Biotechnol Adv. 2016 Sep-Oct;34(5):740-753. doi: 10.1016/j.biotechadv.2016.03.009. Epub 2016 Apr 13. Review.

PMID:
27086202
26.

Adipose-Derived Stem Cells as a Tool for Dental Implant Osseointegration: an Experimental Study in the Dog.

Bressan E, Botticelli D, Sivolella S, Bengazi F, Guazzo R, Sbricoli L, Ricci S, Ferroni L, Gardin C, Velez JU, Zavan B.

Int J Mol Cell Med. 2015 Fall;4(4):197-208.

27.

Mesenchymal Stem Cells Increase Neo-Angiogenesis and Albumin Production in a Liver Tissue-Engineered Engraftment.

Carraro A, Buggio M, Gardin C, Tedeschi U, Ferroni L, Zavan PB.

Int J Mol Sci. 2016 Mar 12;17(3):374. doi: 10.3390/ijms17030374.

28.

Pulsed magnetic therapy increases osteogenic differentiation of mesenchymal stem cells only if they are pre-committed.

Ferroni L, Tocco I, De Pieri A, Menarin M, Fermi E, Piattelli A, Gardin C, Zavan B.

Life Sci. 2016 May 1;152:44-51. doi: 10.1016/j.lfs.2016.03.020. Epub 2016 Mar 12.

PMID:
26979772
29.

Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.

Fraison JB, Mekinian A, Grignano E, Kahn JE, Arlet JB, Decaux O, Denis G, Buchdahl AL, Omouri M, Maigne G, Aouba A, Leon N, Berthier S, Liozon E, Park S, Gardin C, Lortholary O, Rossignol J, Fenaux P, Fain O, Braun T.

Leuk Res. 2016 Apr;43:13-7. doi: 10.1016/j.leukres.2016.02.005. Epub 2016 Feb 20.

30.

Graphene in Regenerative Medicine: Focus on Stem Cells and Neuronal Differentiation.

Gardin C, Piattelli A, Zavan B.

Trends Biotechnol. 2016 Jun;34(6):435-437. doi: 10.1016/j.tibtech.2016.01.006. Epub 2016 Feb 12. Review.

PMID:
26879187
31.

Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.

Vidal-Petiot E, Rea D, Serrano F, Stehlé T, Gardin C, Rousselot P, Peraldi MN, Flamant M.

Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):169-74. doi: 10.1016/j.clml.2015.12.001. Epub 2015 Dec 20.

PMID:
26795084
32.

An update of current treatments for adult acute myeloid leukemia.

Dombret H, Gardin C.

Blood. 2016 Jan 7;127(1):53-61. doi: 10.1182/blood-2015-08-604520. Epub 2015 Dec 10. Review.

33.

Novel Nanotechnologies for Brain Cancer Therapeutics and Imaging.

Ferroni L, Gardin C, Della Puppa A, Sivolella S, Brunello G, Scienza R, Bressan E, D'Avella D, Zavan B.

J Biomed Nanotechnol. 2015 Nov;11(11):1899-912. Review.

PMID:
26554151
34.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F.

Leukemia. 2016 Apr;30(4):897-905. doi: 10.1038/leu.2015.296. Epub 2015 Oct 26.

35.

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.

Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C.

Oncotarget. 2015 Dec 8;6(39):42345-53. doi: 10.18632/oncotarget.5645.

36.

A Novel In Vitro Technique for Assessing Dental Implant Osseointegration.

Sivolella S, Brunello G, Ferroni L, Berengo M, Meneghello R, Savio G, Piattelli A, Gardin C, Zavan B.

Tissue Eng Part C Methods. 2015 Nov 19. [Epub ahead of print]

PMID:
26443415
37.

Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.

Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, Kahn JE, Hamidou M, Park S, Puéchal X, Toussirot E, Falgarone G, Launay D, Morel N, Trouiller S, Mathian A, Gombert B, Schoindre Y, Lioger B, De Wazieres B, Amoura Z, Buchdaul AL, Georgin-Lavialle S, Dion J, Madaule S, Raffray L, Cathebras P, Piette JC, Rose C, Ziza JM, Lortholary O, Montestruc F, Omouri M, Denis G, Rossignol J, Nimubona S, Adès L, Gardin C, Fenaux P, Fain O.

Rheumatology (Oxford). 2016 Feb;55(2):291-300. doi: 10.1093/rheumatology/kev294. Epub 2015 Sep 8.

PMID:
26350487
38.

Persistence of CD34 Stem Marker in Human Lipoma: Searching for Cancer Stem Cells.

Zavan B, De Francesco F, D'Andrea F, Ferroni L, Gardin C, Salzillo R, Nicoletti G, Ferraro GA.

Int J Biol Sci. 2015 Jul 18;11(10):1127-39. doi: 10.7150/ijbs.11946. eCollection 2015.

39.

Decellularization and Delipidation Protocols of Bovine Bone and Pericardium for Bone Grafting and Guided Bone Regeneration Procedures.

Gardin C, Ricci S, Ferroni L, Guazzo R, Sbricoli L, De Benedictis G, Finotti L, Isola M, Bressan E, Zavan B.

PLoS One. 2015 Jul 20;10(7):e0132344. doi: 10.1371/journal.pone.0132344. eCollection 2015.

40.

Immunomodulatory Role of Adipose-Derived Stem Cells on Equine Endometriosis.

Falomo ME, Ferroni L, Tocco I, Gardin C, Zavan B.

Biomed Res Int. 2015;2015:141485. doi: 10.1155/2015/141485. Epub 2015 Jun 9.

41.

Treatment by Therapeutic Magnetic Resonance (TMR™) increases fibroblastic activity and keratinocyte differentiation in an in vitro model of 3D artificial skin.

Ferroni L, Bellin G, Emer V, Rizzuto R, Isola M, Gardin C, Zavan B.

J Tissue Eng Regen Med. 2017 May;11(5):1332-1342. doi: 10.1002/term.2031. Epub 2015 Jun 5.

PMID:
26053437
42.

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.

Herbaux C, Duployez N, Badens C, Poret N, Gardin C, Decamp M, Eclache V, Daliphard S, Murati A, Cony-Makhoul P, Cheze S, Beve B, Lacoste C, Prebet T, Hunault-Berger M, Maloisel F, Renneville A, Figeac M, Stamatoullas-Bastard A, Bastard C, Fenaux P, Preudhomme C, Rose C; GFM (Groupe Francophone des Myelodysplasies).

Am J Hematol. 2015 Aug;90(8):737-8. doi: 10.1002/ajh.24073.

43.

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.

Coudé MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C.

Oncotarget. 2015 Jul 10;6(19):17698-712.

44.

Osteogenic potential of human adipose-derived stromal cells on 3-dimensional mesoporous TiO2 coating with magnesium impregnation.

Cecchinato F, Karlsson J, Ferroni L, Gardin C, Galli S, Wennerberg A, Zavan B, Andersson M, Jimbo R.

Mater Sci Eng C Mater Biol Appl. 2015;52:225-34. doi: 10.1016/j.msec.2015.03.026. Epub 2015 Mar 25.

PMID:
25953562
45.

Tissue Engineering Strategies as Tools for Personalized Meningioma Treatment.

Ferroni L, Della Puppa A, D'Avella D, Isola M, Scienza R, Gardin C, Zavan B.

Artif Organs. 2015 Jul;39(7):E114-26. doi: 10.1111/aor.12483. Epub 2015 Apr 20.

PMID:
25894852
46.

A hyaluronan-based scaffold for the in vitro construction of dental pulp-like tissue.

Ferroni L, Gardin C, Sivolella S, Brunello G, Berengo M, Piattelli A, Bressan E, Zavan B.

Int J Mol Sci. 2015 Mar 2;16(3):4666-81. doi: 10.3390/ijms16034666.

47.

Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.

Harel S, Cherait A, Berthon C, Willekens C, Park S, Rigal M, Brechignac S, Thépot S, Quesnel B, Gardin C, Adès L, Fenaux P, Braun T.

Leuk Res. 2015 May;39(5):501-4. doi: 10.1016/j.leukres.2015.02.004. Epub 2015 Feb 16.

PMID:
25735917
48.

Adult stem cells properties in terms of commitment, aging and biological safety of grit-blasted and Acid-etched ti dental implants surfaces.

Gardin C, Ferroni L, Bressan E, Calvo-Guirado JL, Degidi M, Piattelli A, Zavan B.

Int J Mol Cell Med. 2014 Fall;3(4):225-36.

49.

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P; European ALMA Investigators.

Leuk Res. 2015 Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31.

PMID:
25601157
50.

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

Peterlin P, Renneville A, Ben Abdelali R, Nibourel O, Thomas X, Pautas C, de Botton S, Raffoux E, Cayuela JM, Boissel N, Terré C, Celli-Lebras K, Castaigne S, Preudhomme C, Gardin C, Dombret H.

Haematologica. 2015 May;100(5):e196-9. doi: 10.3324/haematol.2014.115576. Epub 2014 Dec 31. No abstract available.

Supplemental Content

Loading ...
Support Center